"10.1371_journal.pone.0030555","plos one","2012-02-15T00:00:00Z","Yin Liang; Kenji Arakawa; Kiichiro Ueta; Yasuaki Matsushita; Chiaki Kuriyama; Tonya Martin; Fuyong Du; Yi Liu; June Xu; Bruce Conway; Jamie Conway; David Polidori; Kirk Ways; Keith Demarest","Johnson & Johnson Pharmaceutical Research & Development, LLC, Spring House, Pennsylvania, United States of America; Pharmacology Laboratory, Mitsubishi Tanabe Pharma Corporation, Toda, Saitama, Japan; Johnson & Johnson Pharmaceutical Research & Development, LLC, La Jolla, California, United States of America; Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, New Jersey, United States of America","Conceived and designed the experiments: YL KA KU YM CK TM FD YL JX BC JC DP. Performed the experiments: YL KA KU YM CK TM FD YL JX BC JC DP. Analyzed the data: YL KA KU YM CK TM FD YL JX BC JC DP KW KD. Contributed reagents/materials/analysis tools: YL KA KU YM CK TM FD YL JX BC JC DP. Wrote the paper: KW KD.","The authors have read the journals policy and have the following conflicts: Drs. Liang, Martin, Du, Conway, Polidori, and Demarest are employees of Johnson & Johnson Pharmaceutical Research & Development, LLC. Drs. Arakawa, Ueta, Matsushita, and Kuriyama are employees of Mitsubishi Tanabe Pharma Corporation, Japan. Canagliflozin (JNJ-28431754/TA-7284) is being developed by Johnson & Johnson Pharmaceutical Research & Development, LLC. in collaboration with Mitsubishi Tanabe Pharma Corporation. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","02","Yin Liang","YL",14,TRUE,11,11,13,2,TRUE,TRUE,FALSE,0,NA,FALSE
